ANT-GROUP
22.10.2020 12:26:06 CEST | Business Wire | Press release
Ant Group, a leader in the development of open platforms for technology-driven inclusive financial services, and the parent company of China’s largest digital payment platform, Alipay, today unveiled its new digital copyright services platform powered by AntChain, the company’s blockchain-based technology. The platform aims to help millions of original creators verify and protect their copyright with greater efficiency and at a lower cost.
Powered by blockchain and AI technologies, the digital copyright services platform enables content creators to quickly authenticate and verify a variety of original works, from music scores to videos, images, and articles and essays. When a creator uploads his or her work onto the platform, the platform will first verify whether the content is the only one that exists within its database. It will then generate a unique digital copyright certification containing basic information about the work, as well as a notary stamp. These tamper-proof certifications can also be submitted as evidence in copyright infringement and tort cases.
The digital copyright services platform also provides identification and search services that can help creators effectively monitor and flag potential copyright infringement, making it easier and less costly for IP owners to verify and protect their original content.
Applying for copyright registration and certification is typically a complicated and time-consuming process. With the digital copyright services platform, this process is effectively shortened to one minute, and creators can save up to 95% in related expenditures.
"We believe that AntChain can play a pivotal role in building trust among multiple parties and solving real-life problems for the copyright industry," said Guofei Jiang, President of Advanced Technology Business Group, Ant Group. “The AntChain-powered digital copyright services platform was specifically designed to address the pain points that creators typically encounter when trying to authenticate and protect their work.”
Shanghai C.C. Music Culture Co Ltd, China's leading digital music score copyright distribution network, was one of the first partners to join the digital copyright services platform during its trial period. Now, musicians who are part of Shanghai C.C. Music Culture’s network can secure digital copyright certifications when they upload their original works to the platform. At the same time, AntChain will generate smart contracts that can record revenues generated by the musicians and the distributor. Once their work is successfully sold, the smart contract is triggered, and revenues will be automatically distributed to the musicians and Shanghai C.C. Music Culture.
Nianhua Yi, CEO of C.C. Music, commented, “The AntChain-powered digital copyright services platform enables the musicians on C.C. Music to register and certify their works with ease. That really brings great benefits for the creators.”
At present, more than 10 million original works are certified every day on the digital copyright services platform.
About AntChain
AntChain is Ant Group’s blockchain business. According to IPR Daily and patent database IncoPat, Ant Group held the highest number of published blockchain-related patent applications between 2017 and the six months ended June 30, 2020. Since the launch of Ant Group’s blockchain business in 2016, the company pioneered the use of AntChain in over 50 blockchain commercial applications and use cases, including supply chain finance, cross-border remittance, charitable donations and product provenance.
The AntChain platform consists of three layers including the underlying Blockchain-as-a-Service open platform, digitalization of assets, and circulation of digitalized assets. By enabling businesses to digitalize their assets and transactions, AntChain establishes trust in multi-party collaborations. The AntChain platform generated over 100 million daily active items such as patents, vouchers, and warehouse receipts, for the twelve months ended June 30, 2020.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201022005573/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom